Investigation of the Disparities in Ultrasound Imaging Features of miR-323, miR-409-3p, and VEGF Expression Scales in Different Clinicopathological Features of Prostate Carcinoma and Their Correlation with Prognosis.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
05
2022
revised:
24
05
2022
accepted:
31
05
2022
entrez:
28
6
2022
pubmed:
29
6
2022
medline:
30
6
2022
Statut:
epublish
Résumé
Prostate carcinoma (PC) is a disease of the male genitourinary system and a relatively common malignant tumor. In order to investigate the disparities in the expression of microRNA-323 (miR-323), microRNA-409-3p (miR-409-3p), and vascular endothelial growth factor (VEGF) in prostate carcinoma with different clinicopathological features and analyze their correlation with prognosis. Thirty-two sufferers with prostate carcinoma and forty-three sufferers with benign prostatic hyperplasia are included. The results show that the detection of miR-323, miR-409-3p, and VEGF scales can provide reference value for clinical guidance of prostate carcinoma prognosis.
Identifiants
pubmed: 35761975
doi: 10.1155/2022/5053204
pmc: PMC9233573
doi:
Substances chimiques
MIRN323 microRNA, human
0
MIRN409 microRNA, human
0
MicroRNAs
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Retracted Publication
Langues
eng
Sous-ensembles de citation
IM
Pagination
5053204Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2022 Bao Liu et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Références
Front Pharmacol. 2021 Apr 13;12:642900
pubmed: 33927622
Mol Cancer Ther. 2013 Aug;12(8):1629-37
pubmed: 23699654
Cancers (Basel). 2021 Jan 05;13(1):
pubmed: 33466359
Genet Mol Biol. 2020 Jun 01;43(3):e20180329
pubmed: 32484847
Tumori. 2020 Oct;106(5):406-412
pubmed: 32116138
J Urol. 2021 Jul;206(1):174
pubmed: 33683938
Contrast Media Mol Imaging. 2022 Apr 8;2022:5764574
pubmed: 35480083
Int J Cancer. 2020 Mar 15;146(6):1686-1699
pubmed: 31381135
Clin Cancer Res. 2014 Sep 1;20(17):4636-46
pubmed: 24963047
BMC Mol Cell Biol. 2021 May 19;22(1):30
pubmed: 34011277
Clin Cancer Res. 2014 Dec 15;20(24):6559-69
pubmed: 25324143
J Urol. 2021 Feb;205(2):444-451
pubmed: 33026934
Biomed Signal Process Control. 2022 Jan;71:103216
pubmed: 34697552
Int J Mol Sci. 2020 Feb 13;21(4):
pubmed: 32070055
Cell Physiol Biochem. 2015;36(4):1491-8
pubmed: 26160610
Front Immunol. 2021 Jan 25;11:586126
pubmed: 33569050
J Healthc Eng. 2022 Jan 25;2022:9389239
pubmed: 35126956
Am J Cancer Res. 2015 May 15;5(6):2083-9
pubmed: 26269767
Nano Lett. 2020 Aug 12;20(8):5844-5852
pubmed: 32589431
Nanomedicine. 2021 Feb;32:102332
pubmed: 33181273
Curr Med Sci. 2021 Jun;41(3):522-528
pubmed: 34169422